Page 4,871«..1020..4,8704,8714,8724,873..4,8804,890..»

Adamas Pharmaceuticals Presents Positive Clinical Data For ADS-5102, A Treatment For Levodopa-Induced Dyskinesia, At …

Posted: Published on October 2nd, 2013

MONTREAL and EMERYVILLE, Calif., Oct. 2, 2013 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. presented positive results today from the Phase 2/3 EASED clinical trial of ADS-5102 at the World Parkinson's Congress. ADS-5102 is Adamas' proprietary long-acting capsule formulation of amantadine HCl in development for the treatment of levodopa-induced dyskinesia (LID) in Parkinson's disease (PD) patients. ADS-5102 met its primary endpoint in the Phase 2/3 clinical trial and demonstrated statistically significant improvements in a number of key assessments of LID. (Logo: http://photos.prnewswire.com/prnh/20130618/LA33709LOGO) "We are extremely pleased with the positive results achieved in our Phase 2/3 EASED trial, and the magnitude of the change in ON time without troublesome dyskinesia in Parkinson's patients suffering from LID. Levodopa-induced dyskinesia is one of the most difficult challenges facing patients with PD, and there are no FDA-approved drug treatments available," said Gregory T. Went, Ph.D., Chief Executive Officer of Adamas. "ADS-5102 reduced both the duration and severity of dyskinesia among PD patients with statistical significance, providing an average of 11.5 hours during the day of ON time without troublesome dyskinesias as compared to 8 hours on placebo. The encouraging data from this trial indicate that ADS-5102 has the potential to positively impact the lives of PD … Continue reading →

Posted in Parkinson's Treatment | Comments Off on Adamas Pharmaceuticals Presents Positive Clinical Data For ADS-5102, A Treatment For Levodopa-Induced Dyskinesia, At …

Patients face 150-mile trip to get Parkinson’s treatment

Posted: Published on October 2nd, 2013

A search has been launched to find somewhere in Shropshire for Parkinsons patients to receive pioneering treatment, after it emerged patients were having to travel as far as Hereford. Patients want to find a venue preferably in Shrewsbury where they can receive treatment after sessions at Megan Baker House in Leominster ceased. About 40 people who travelled across the Shropshire border to make use of the service now face a 10-mile longer journey to Hereford leaving people travelling from north Shropshire with a potential round trip of 150 miles. The Parkinsons sufferers also need to find custom-made treatment furniture for the conductive education treatment, developed by physician Professor Andras Pto in Hungary, which embraces learning and development of movement, speech and mental ability. The treatment is also used to help those living with cerebral palsy, multiple sclerosis, strokes or head injuries. Brenda Hodnett, from Shrewsbury, has suffered from Parkinsons for three years and has been having the treatment for several months. She said: We have been to see a variety of venues to try and find a space where we can have the treatment. But the rooms have either been too small, with the wrong flooring, or there hasnt been … Continue reading →

Posted in Cerebral Palsy Treatment | Comments Off on Patients face 150-mile trip to get Parkinson’s treatment

1st Cerebral Palsy of New Jersey Unveils New Website

Posted: Published on October 2nd, 2013

BELLEVILLE, NJ--(Marketwired - Oct 2, 2013) - 1st Cerebral Palsy of New Jersey, a highly-acclaimed, non-profit private school for students with disabilities, today announced the launch of the organization's new website. A pioneer in providing education, treatment and recreation for individuals with all types of special needs, the organization's new website is a one stop resource for education, therapy and special programs to assist with the development of special needs children.The new site can be accessed at http://www.cerebralpalsycenter.org. A complete rebranding of the 1st Cerebral Palsy of New Jersey online presence, the new design reflects the organization's mission to assist all students with special needs to lead more active and productive lives. Featuring a user-friendly interface, streamlined navigation and fresh design, the site boasts information about clubs, sports programs, and the extended school year program offered at the school -- programs that many traditional schools don't offer students. "We have a long rich history and are proud to provide students with unique learning experiences that will enable them to reach their highest potential," said 1st Cerebral Palsy of New Jersey Executive Director Patrick Colligan. "Our old site was outdated and didn't reflect the vision of our school. The new site … Continue reading →

Posted in Cerebral Palsy Treatment | Comments Off on 1st Cerebral Palsy of New Jersey Unveils New Website

Details released about accident that led to Lexi Bolstad's severe brain injury

Posted: Published on October 2nd, 2013

FARGO New details have emerged about the GEM car accident two months ago that left Davies High School senior Alexis (Lexi) Bolstad with a critical brain injury. A police report filed in connection with the incident paints a detailed picture of the night Bolstad fell from the GEM car an electric vehicle similar to a golf cart. Four teens, including Bolstad, were in the vehicle headed south on Veterans Boulevard around 9:15 p.m. on Aug. 4, according to the report. Witnesses told police Bolstad was hanging off the side of the GEM car and waving her arm and yelling as the car entered the roundabout to travel on 44th Street. She lost her footing, fell from the vehicle onto her back and struck her head on the pavement. Bolstad was transported to Essentia Health in Fargo for treatment, where she stayed in the intensive care unit for a month. Bolstad initially underwent surgery to have parts of her brain removed. She was heavily sedated and could not breathe or eat on her own. In early September, she was moved to Craig Hospital in Denver, which specializes in spinal cord and brain injury rehabilitation. The Bolstad family has documented her improvement … Continue reading →

Posted in Brain Injury Treatment | Comments Off on Details released about accident that led to Lexi Bolstad's severe brain injury

Burke Rehabilitation Hospital's Dr. Barry Jordan to Receive Champion of Hope Award from Brain Injury Association of …

Posted: Published on October 2nd, 2013

White Plains, NY (PRWEB) October 02, 2013 Burke Rehabilitation Hospital has announced that Barry Jordan, M.D., MPH, assistant medical director, will be honored with the 2013 Champion of Hope Award by the Brain Injury Association of New York State (BIANYS) at the organizations annual gala to be held on Oct. 8 at 6:30 p.m. at Slate Restaurant (54 West 21st Street) in New York City. Dr. Jordan is a renowned neurologist who has been with Burke since 1999, first as an attending neurologist and then director of Burkes inpatient Brain Injury program and medical director of the Memory Evaluation and Treatment program. Earlier this year, Dr. Jordan was promoted to assistant medical director while continuing to serve as director of the Brain Injury program. For more than a decade Dr. Jordan has been an invaluable member of the Burke Rehabilitation team, says Mary Beth Walsh, M.D., Burkes CEO and executive medical director. He has expanded our brain injury services, helped improve patient outcomes and had a positive impact on patients lives. Additionally, his work with the Brain Injury Association of New York State as an advocate for patients with brain injuries has been influential and he is very deserving of … Continue reading →

Posted in Brain Injury Treatment | Comments Off on Burke Rehabilitation Hospital's Dr. Barry Jordan to Receive Champion of Hope Award from Brain Injury Association of …

MS treatment reduces brain tissue damage, Teva and Active Biotech say

Posted: Published on October 2nd, 2013

TEL AVIV (Reuters) - Israel's Teva Pharmaceutical Industries and Sweden's Active Biotech said a Phase III clinical trial of laquinimod, an oral treatment for multiple sclerosis, demonstrated a beneficial impact on brain tissue damage. The study found that, compared with a placebo, patients treated with laquinimod had decreased rates in brain tissue damage shown by various MRI markers, specifically decreased rates of white matter, grey matter and thalamic atrophy, the companies said on Tuesday. The patients also developed fewer permanent black holes and accumulated less damage in normal appearing brain tissue. "These analyses reinforce our faith in the potential of laquinimod," said Michael Hayden, president of global research and development and chief scientific officer for Teva. He announced plans to initiate a clinical trial of the drug in primary progressive multiple sclerosis. "We also believe the potential neuroprotective benefits of laquinimod could have significant application in the treatment of other diseases like Crohn's disease, lupus nephritis, Huntington's disease and Alzheimer's," Hayden said. (Reporting by Tova Cohen) See more here: MS treatment reduces brain tissue damage, Teva and Active Biotech say … Continue reading →

Posted in MS Treatment | Comments Off on MS treatment reduces brain tissue damage, Teva and Active Biotech say

GW Pharmaceuticals Announces New Sativex® Data at ECTRIMS

Posted: Published on October 2nd, 2013

LONDON, Oct. 2, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (AIM: GWP, Nasdaq: GWPH, "GW") announced that data from new MS spasticity studies (clinical trial data, observational study data and registries data collection) is being presented today at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark. The following press release was issued today by GW's commercial partner, Almirall S.A., regarding the data presentation: Copenhagen, Denmark, 2nd October 2013: Almirall S.A. (ALM) today announces the latest evidence with Sativex (THC:CBD spray) from new MS spasticity studies (clinical trial data, observational study data and registries data collection). These data, presented today at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark, show that Sativex effectiveness is maintained long term with no additional safety concerns identified in clinical practice. Two-thirds of the more than 2,000 patients with MS surveyed in the recent Spanish "6E" study reported a certain degree of spasticity, being moderate or severe in 40% of them.i "Sativex can improve the spasticity symptoms impairment of MS patients without affecting such issues as driving ability, cognition or mood," says Dr. Tiina Rekand, of the … Continue reading →

Posted in MS Treatment | Comments Off on GW Pharmaceuticals Announces New Sativex® Data at ECTRIMS

New First-In-Class Epilepsy Treatment Fycompa® (Perampanel) launches in Republic of Ireland

Posted: Published on October 2nd, 2013

HATFIELD, UK, October 2, 2013 /PRNewswire/ -- Fycompa (perampanel), the first in an entirely new class of treatment for uncontrolled partial onset seizures (the most common form of epilepsy), launches today in Ireland. The new therapy is indicated for the adjunctive treatment of partial onset seizures, with or without secondarily generalised seizures, in patients with epilepsy aged 12 years and older.[1] Perampanel is the only licensed anti-epileptic drug (AED) to selectively target AMPA receptors, a protein in the brain which plays a critical role in the spread of seizures.[2] This mechanism of action is different to other, currently available AEDs. In addition, perampanel has the added benefit of convenient, once-daily dosing at bedtime[1] and, significantly, is the only new-generation partial epilepsy treatment approved to treat adolescents with epilepsy from launch. Epilepsy is one of the most common neurological conditions in the world.[3] Around 37,000 people in Ireland live with the condition.[4] "Almost a third of people with partial epilepsy continue to experience seizures despite the treatment options currently available," commented Professor Norman Delanty, Consultant Neurologist at the Beaumont Hospital. "New treatment options such as this are a welcome addition to doctors' epilepsy treatment armamentarium." Perampanel's approval in Ireland is based … Continue reading →

Comments Off on New First-In-Class Epilepsy Treatment Fycompa® (Perampanel) launches in Republic of Ireland

The last word on hormone therapy?

Posted: Published on October 2nd, 2013

By Leslie Wade, CNN CNN When Janice hit menopause, she had terrible night sweats and hot flashes, but she was scared to undergo hormone replacement therapy. Janice (who asked that her full name not be used for privacy reasons) had heard this treatment might be dangerous to her heart, and worried about risking her health. Its a concern many American women have shared over the past decade since the benefits of hormone replacement therapy have been called into question. A large study called the Womens Health Initiative (WHI) was instrumental in casting doubt on these hormones. Tuesday, scientists from the WHI released what they say is the definitive study on the safety of hormone replacement therapy (HRT). The bottom line: Its OK for most healthy women who have just entered menopause to take hormones for a short period of time, but the researchers do not recommend it for long-term use. The results are published in this weeks Journal of the American Medical Association. Background Hormone replacement therapy is used to replace estrogen and other female hormones that are no longer produced after menopause. For decades, doctors thought HRT was good for womens hearts and prescribed it, in part, to prevent … Continue reading →

Posted in Hormone Replacement Therapy | Comments Off on The last word on hormone therapy?

Hormone replacement therapy less risky for women in their 50s, latest data suggest

Posted: Published on October 2nd, 2013

In the decade since a landmark study uncovered the risks of taking hormone replacement therapy for disease prevention, some doctors have shied away from prescribing the drugs even for women with severe hot flashes and other menopausal symptoms. But the latest followup data from the Womens Health Initiative trial involving 27,000 postmenopausal women suggest that the benefits of symptom relief outweigh the risksat least for women in their 50s. Among women between 50 and 59, increased risks associated with taking a combination of estrogen and progesteronesuch as strokes, blood clots, and breast cancerwere very small, less than 1 percent during the five years they were taking the hormones, according to the research published Tuesday in the Journal of the American Medical Association. Women in the trial who were still experiencing menopausal symptoms had significant improvement in these symptoms when taking hormone therapy compared to a placebo and had a very low risk of adverse events, said Dr. JoAnn Manson, principal investigator of the Womens Health Initiative and chief of preventive medicine at Brigham and Womens Hospital. While the heightened breast cancer risk was small, it persisted for at least six years after women stopped taking the combination therapy. But hormone … Continue reading →

Posted in Hormone Replacement Therapy | Comments Off on Hormone replacement therapy less risky for women in their 50s, latest data suggest

Page 4,871«..1020..4,8704,8714,8724,873..4,8804,890..»